Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great, they have started Phase 1 of BP 2001. The web site says:
BP1002 (Liposomal Bcl2 Antisense)
Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.
so they are only 3 3/4 years behind schedule. Meanwhile PN is taking a huge salary drawing down the limited funds.
Whoopy ding. Now if we could see what the hell progress they have made since 2016 things might look even better.
The press release references the web site. This contains the wonderfully hopeful statements that kept us happy four years ago, before the disillusionment and the 200:1 RSS. Remember when we loved reading:
++++++++++++++++++++++++
Current Development Status
- Based on successful results of a Phase 1 clinical trial, Bio-Path has initiated a Phase 2 program in AML, comprised of two clinical trials of BP1001 in combination with the first-line standard-of-care chemotherapy, low dose Ara C (LDAC):
The first has been initiated in 54 newly diagnosed AML patients who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
A second study in relapsed and refractory AML patients is expected to be initiated in 2017.
- Prexigebersen has also completed a Phase 1 clinical trial in patients with CML and expects to initiate enrollment before the end of 2016 for the dose-determining segment of a Phase 2 trial of prexigebersen in combination with first-line standard-of-care for CML, dasatinib.
+++++++++++++++
WOW. THe expectations for 2016 and 2017.
WHAT HAPPENED???
WTF has been done in the four years since that "Current Status" was written?
Where have they spent all that money?
Presentations to try to get new investment are not what is needed. What is needed are presentations by credible scientists on what has been done in the last four years and what results have been obtained.
So PN is going on the road again after ?how many years? to try to re kick start this scam. He will surely drone on in his own inimical boring manner over mostly three year old results. How many decades can he keep this up?
http://www.globenewswire.com/news-release/2020/09/09/2090818/0/en/Bio-Path-Holdings-to-Present-at-the-H-C-Wainwright-22nd-Annual-Global-Investment-Conference.html
The link says the study started in May 2016. WOW. Those were the days!!! I remember we on this message board thought we would have results by the end of 2017 and we would not only be rich but would have helped humanity overcome another scourge.
The stock hit $638 (pre 200:1 RSS adjusted). Happy days.
It would be kinda interesting to know what progress there is. How many of the 108 (if any) have actually been in treatment and if any have shown remission. I recall that it started with needing 21 (or thereabouts), how the heck did it get to 108?
The web site says:
BP1002 (Liposomal Bcl2 Antisense)
Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.
Still planning for 2017 I see - have they missed the boat?
I stick with my belief that this was a hoax from the start and any remaining stock holders (such as me) are just being strung along in the hope we don't wise up and sue. Has anyone been to the office address to see if it looks like a real operation, not just a conman and secretary living it up.
You still believe!!
I would not be surprised if this went down below 5cents again and PN did a 20:1 RSS. Keep milking until the cow croaks.
It is becoming harder and harder to avoid the subversive thought that this was a scam right from the start. The principles have made their fortunes, all believers have lost although some clever people have made money predicting the movement and trading.
Is there anyone reading this that can drop by the offices in Texas to see if there are actually people there?
As an old investor (both by age and by length of time in this mess) I seldom bother to check to see what is going on; when you've been 200:1 buggered what is the point? (yes, that is a whine, live with it). However I took a look today to see if the world is any closer to a cancer cure and was disappointed that the BPTH web site is three years or more out of date; it refers to:
A second study in relapsed and refractory AML patients is expected to be initiated in 2017.
and:
- Prexigebersen has also completed a Phase 1 clinical trial in patients with CML and expects to initiate enrollment before the end of 2016 for the dose-determining segment of a Phase 2 trial of prexigebersen in combination with first-line standard-of-care for CML, dasatinib.
and:
Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.
I took a quick look at the 2020 slide show :
http://www.biopathholdings.com/wp-content/uploads/2020/01/BPTH_Corp_Presentation_Jan_2020.pdf
and the results on slide 8 9 10 are what I remember (no I didn't verify) from 2017
I remember the halcion days of 2016 and 2017, it seems the company hasn't moved on since then!!! Does anyone know if they are even still working on this or are they just sitting with their thumbs up their bums enjoying a free ride until the money runs out?
Just asking.
Not much new in the webcast. I note the burn rate is $2M per quarter with $17.1M cash in hand at end of June. With a bit of luck (and a lot of good management) we'll get results to send this stock up like a rocket before we need more cash.
http://wsw.com/webcast/hcw5/bpth/index.aspx
It has been said that those who don't know history are doomed to repeat it, it is also a proverb the any fool can learn from their own mistakes, wise people learn from the mistakes of others.
I got sucked in to this years ago - silly expectation of profit. Like all long term followers of this company I recognize that it isn't going anywhere without solid results. PN uses smoke and mirrors to raise funds and we all have suffered huge losses 99.5% to 99.9% depending on when you jumped in; hopefully we all knew it was high risk and didn't put on more than we could afford to lose.
From time to time PN sucks in a new bunch of investors, we see a huge surge as they enthusiastically embrace the promise then a slow decline as reality sinks in. The cash position after the last episode is good enough that no new financial wizardry (duplicity) will be necessary for one or two years then it will repeat.
If ever there are results we wait (not with bated breath - we would die) to see if they have any of the requisite knowledge and skills to bring a product to market and actually make money.
Thanks for that STOCK.
Skimming through the transcript I didn't see anything new that was concrete, maybe I missed it but it looked like more rehash of old news. It will be interesting to see if PN bothers to do anything more for the next year or two to stave off the slow decline in pps and another RSS.
I have to say that I admire his resourcefulness in getting hard cash for old rope over the last few years, now if only he could find a way to push the science forward he would rate as a true genius.
People are trying hard, but I fear that the only one who can generate enough hot air to make this thing fly is PN, and until he needs cash (in about three years time)he has no real interest.
It almost seems as if some people posting on this board are on whacky baccy!
https://finance.yahoo.com/news/bio-path-holdings-announce-first-200100325.html
What do you mean by "earnings" Captain? This outfit is a money pit that only goes up when the board needs money and does some fancy footwork to boost pps. Historically they relied on presentations at conferences, then a traveling road show, then a 10:1 reverse stock split, then a con job on speculation investment firms, then another RSS - this time 20:1, then some sort of con job new share issue - though why the hell anyone fell for that is beyond me.
They were nearly broke at the end of 2018, the weird stock offering got them about 3 years money so don't expect any new fancy share price boosting scheme until they run out again in about 2021.
Only results will save us. We expected Phase II results for 19 evaluatable patients in the summer of 2017. They announced 17 at the end of the year in a desperate attempt to raise funds but we are still waiting on the other two a year and a half later.
Keep dreaming all you like, but until there are results, or another soft shoe shuffle by PN, expect slow but certain decline - it is a historically demonstrated truth!!!!
I am a reasonably ignorant investor who got sucked in to the BPTH hype a few years ago and is now just a wounded onlooker.
PStates is dead on, the surge and slow decline has been repeated since the company went public and the only certainty we can get from history is that each decline takes the stock to a much lower price. A $10 share (it is coming soon) now is 5cents per original (pre 200:1 RSS) share. Expect less than a dollar within this year and another RSS and a financial finagle by PN et al when they, again, run out of funds.
As a retired computer person I realize that the "technical prophesies" are bullshit unless the company has a spectrum of investors with a defined behavior history used to derive a model of the company stock price movement. I seriously doubt that the holders of BPTH have a behavior pattern the same as that used by financial computer programmers; that means that computer predictions are based on a wholly erroneous presumption.
Give up. If you are ahead, or even a little behind, then get out now, don't join us bitter and wounded bystanders.
I repeat my previous question, what information do you have that Phase 2 is anywhere near completion?
We were led to believe the end of Phase 2 was close in the spring of 2017, and were sure by November 2017. Have you any evidence to believe that there are any patients at all enrolled? And I mean evidence, not just BPTH propaganda.
How the present management got this scam rebooted is a mystery, why investors are backing a proven looser an even greater puzzle.
expertpro you may be right, but some of us believed this in November 2017 (200x stock reverse splits ago). I agree that we are 14 months closer now than we were then, but we are also 14 months closer to the apocolypse, WW 3, and the end of civilization as we know it.
If you have any information or knowledge that we are actually "close" please share. For discussion I will define CLOSE as less than 12 months. Those of us who have lost much have nothing to lose now, but if you encourage a new band of bright eyed investors down this primrose path you are doing a grave disservice to humanity.
This company "seemed" to have good science but through terrible management has driven the whole thing under a freight train. It might be possible to revive the science but if, as some seem to believe, this is a Wasach front scam then this is merely a reboot of an old hustle. Put in a new, credible, CEO and BOD and then perhaps it would be worth promoting but under the old management it is doomed.
WHOO HOOO. Soon be at $560 and some of us will break even. I'm only 74 so it could happen in my lifetime. Maybe.
I compared the December 29 2017 clinical update and business outlook with the December 27 2018 document. Some items are obviously cut and pasted such as:
Two cohorts of three evaluable patients each are expected to be enrolled to evaluate two doses (60 mg/m2 and 90 mg/m2) of prexigebersen in combination with dasatinib.
Plans for a pivotal trial will be discussed with the FDA if these results exceed expectations for current standard of care therapy
In 2017 PN said:
To-date in this study, over 50 potential patients have been pre-screened, 26 patients have been screened, 23 patients have been enrolled and 17 patients have been deemed evaluable with 6 additional patients currently undergoing treatment. Bio-Path expects the 19 patient pre-specified analysis to be completed in early 2018, at which time the assessment of these patients will be addressed by Bio-Path.
and now:
As previously announced, a planned interim analysis of Stage 1 of the study was performed on 17 evaluable patients, with four patients achieving complete responses (24%) and four patients achieving stable disease, including one patient achieving a morphologic leukemia free state and one patient who showed significantly reduced bone marrow blasts. In total, 47% of the evaluable patients showed some form of response, including stable disease, to the prexigebersen and LDAC combination treatment.
OK, this we knew. Then further:
In August 2018, Bio-Path announced first patient dosed in Stage 2 of the open-label Phase 2 study evaluating the efficacy and safety of prexigebersen (an antisense RNAi nanoparticle against Grb blah blah blah In 2019, Bio-Path expects to open three trial sites in the EU, which Bio-Path expects will accelerate patient enrollment.
So no progress on the original 19 in the whole year, let alone “in early 2018” and there would seem to be no new enrollments.
In Dec 2017
Phase 2a Study of Prexigebersen in Accelerated and Blast Phase CML Patients
Bio-Path today announces the initiation of its Phase 2a clinical study of prexigebersen for the treatment of chronic myeloid leukemia (CML) . . . . blah blah blah
Dec 2018
Phase 2a Study of Prexigebersen in Accelerated and Blast Phase CML Patients
Bio-Path plans to continue enrolling patients in 2019 in a Phase 2a clinical study of prexigebersen in combination with the frontline therapy, dasatinib, for the treatment . . . . blah blah blah
It would be nice to have some idea of how many patients have been enrolled in a year.
I give up on the comparisons. Amid all the waffle and long words there is nothing positive at all. It is clear that any progress is so insignificant and slow that there is no chance whatsover of completing even one of these studies before the money runs out in the spring. SABBY must be feeling really ripped off over getting sucked in in August!!!
Can anyone see any hope at all?
Sorry I am ignorant, but can someone explain what this means please.
https://seekingalpha.com/filing/4282627
https://seekingalpha.com/filing/4282613
https://www.sec.gov/Archives/edgar/data/1133818/000114420418066409/tv509953_ex99-1.htm
The latest poster presentation looks to me like LAST YEAR"s DATA - 17 evaluable patients, or did I miss something? What has happened since they revised the dosage nearly a year ago? Can we assume that the science has failed? Did PN put up another presenter because he was too ashamed to stand up in public?
Any opinions on how we should vote?
Pardon my ignorance, but how does a RRS get us any more money? To get money someone has to believe in the company and share price won't make any difference.
I understand that an RSS would keep BPTH in compliance with the NASDAQ share price rule but won't it put us risk of a deeper hole and never be able to meet the market cap criterion?
Just asking because someone out there knows the answers and I am too lazy and disinterested to research this.
Stupidity and ineptitude are not culpable offences are they? PN is OK so long as he put some of his salary under his mattress.
Musing on this in my ignorant way it seems to me that the investing comunity has different cohorts and the cohort of people who invested in BPTH in the good old days was/is limited in size. PN used conferences and travelling road shows to make sure he "saturated" this market but didn't recognise that it was finite. He reached the end but still desparately tried the same tricks again but there was noone there.
We have some technical gamblers moved in because they fancy the odds, sort of like people betting on a horse just because the odds are 400:1, I hope it pays off for them, not becuase I like (or dislike) them as a group but because they have injected a little optimism into a bleak prospect. They can't boost the stock price, they have no real substance.
Only positive Phase II results can save the company. It is entirely probable that a positive result would result in a buy out by a company with the resources to carry this science through to market. The stock market won't supply any new money, just keep recycling shares through the gambling comunity.
Nothing good? I don't see the massive compensation package for our BOD on the agenda so that is a not not-good. A double negative is not a positive, I suppose, but at least we are spared seeing PN and cronies sucking the life blood of the company this year.
"Pump" to me is only half of "Pump and Dump" a scenario I have lost money on in the past. Hopefully we see wonderful test results, FDA fast track, a sustained stock rise, and healthy gains and everlasting dividends for all the faithfull!!
I got this link in my email;
https://www.sec.gov/Archives/edgar/data/1133818/000153561018000099/0001535610-18-000099-index.htm
I took this at face value, that Sabby were rolling some BPTH into a hedge fund in the expectation of profit, and that BioPath was getting money to keep research on track.
PN et al must have convinced Sabby that results are coming very soon, that FDA blessings will fall on BPTH, that the stock will rise, that they will make a lot of money.
We must ask if Sabby is so dumb as to fall for an improbable line, if we believe in the science, if it is possible that studies are near a positive conclusion, if it is possible that this bail out will get us though to the halcion days we have awaited so long?
I believe. Sabby must be more competent than our board so I trust their judgement. Let's be cool, be happy; there's bugger all else we can do to shape the future. There abideth Faith, Hope, and Love, so we may as well have hope in our hearts and relax and watch the future unfold.
Hey, come on, lets look on the bright side.
PN based his strategy on giving road shows and presentations to raise cash but this stopped working leaving him few options.
We already lost something like 97% of our money so another % or so is neither hear nor there; you can't lose much when there is little left to lose. Dreams of wealthy retirement are shot so just let them go. I had planned to buy a new motorcycle but bought a used electric scooter instead.
An institutional investor has chosen to sink a good chunk of money into BPTH which means PN & Co must have spun them a good line and they must have done due diligence and checked it out therefore there is good reason to hope that there will be good news soon. We won't all get rich like we hoped but we should get a bit back.
Another bright point, the new investor might just tip the scales next general meeting and dump the chump!!
You probably all know this but just in case someone else is as ignorant as me.
Last night (while crying in my scotch) I placed a sell order for a chunk of BPTH to buy some cannabis stock. In depression I just clicked on Sell-At-Market.
I just got a call from my on-line broker firm (45 min before market open) that someone has a large standing buy order at 1 cent so there was a possibility that my entire sell order would have gone through to this person. That would have been a KO to the jaw after the repeated kicks in the nuts we have all been suffering.
Just a heads up for my fellow ignoramuses
As I understand that announcement there will be TWO cohorts, each with an end point of "approximately 19" evaluable patients, one cohort treated in combination with LDAC and a second separate cohort treated in combination with decitabine. That sounds like double the work so the money will run out very quickly.
Perhaps we can look forward to a share price in the $4 - $10 range following another 10:1 RSS. That puts the old (last year!) $30 dream pps at $3,000. In the words of a certain important person "Sad. Very very Sad".
A year or so ago I asked if there was anyone in Houston who could call by the address to make sure there was at least a legit looking front but noone responded.
I really hope this is a stupid question, but can they do another 10:1 RSS on the strength of that vote last December or are they limited to just the one until another general meeting?
Silly question. Of COURSE he needs a raise to compensate for the loss in value of his share holdings.
Maybe this time you are wrong to think you are wrong.
I got to thinking and musing while crying in my coffee. We had two nice big runs up. $5 (pre-RSS) in 2014 and $3 (pre-RSS) in 2016. What were these based on? I suggest they were fuelled by hope and greed, and a smallish band of investors kinda egged each other on with no real basis. I think it is called a bubble and I recall learning about the first one (South Sea Bubble of 1711 - 1720) in high school history.
We finally got some real news in March and a possibly genuine rise began but rapidly collapsed. I suggest that the small band of BPTH holders started to get exited but, twice bitten and still hurting from market fever, didn't sustain it; there were too few new enthusiasts to fuel the rise.
I want to get some of my money back and, in the absence of a buy out, that objective will need new, unburned, bright eyed, bushy tailed believers to get this stock kick started again. May I suggest that, notwithstanding provocation, disgust, anger, hurt, etc we stop knocking the company and its leadership. Not endorsing (that would be self-serving and immoral) but just maintaining a dignified silence to allow newbies to drive this lead bubble up to the point where I can bail out.